EP1401466B1 - Agent contenant de la graisse(de l'huile) et un extrait d'oignon, sa production et son utilisation pour soigner, prevenir ou traiter des tissus cutanes endommages, notamment des cicatrices - Google Patents

Agent contenant de la graisse(de l'huile) et un extrait d'oignon, sa production et son utilisation pour soigner, prevenir ou traiter des tissus cutanes endommages, notamment des cicatrices Download PDF

Info

Publication number
EP1401466B1
EP1401466B1 EP02760209A EP02760209A EP1401466B1 EP 1401466 B1 EP1401466 B1 EP 1401466B1 EP 02760209 A EP02760209 A EP 02760209A EP 02760209 A EP02760209 A EP 02760209A EP 1401466 B1 EP1401466 B1 EP 1401466B1
Authority
EP
European Patent Office
Prior art keywords
oil
mixtures
agent according
onion extract
additives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02760209A
Other languages
German (de)
English (en)
Other versions
EP1401466A1 (fr
Inventor
Valentina Paspaleeva-Kühn
Rolf D. Beutler
Simone Schatschneider
Martina Heberer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Priority to EP05009586A priority Critical patent/EP1566179B1/fr
Priority to DK02760209T priority patent/DK1401466T3/da
Publication of EP1401466A1 publication Critical patent/EP1401466A1/fr
Application granted granted Critical
Publication of EP1401466B1 publication Critical patent/EP1401466B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a novel fat (oil) -containing agent containing Onion extract, as well as its production and use for the preparation of compositions to care, Prevention or treatment of damaged skin tissue, e.g. to Operations, biopsies, cuts, burns and other accidents, as well as in particular of scars, stretch marks, degenerative Skin changes, etc.
  • the agent is characterized in that it has a Oil base and thus insofar as e.g. on cream, lotion, fluid, massage oil or balsam base can be prepared. It is therefore fat (oil).
  • the onion extract which in particular water, Alcohol, or even water-alcohol-containing, is in such an oily base be installed without affecting its effectiveness or any Phase separation occurs. The effectiveness could be in medical Application observations are demonstrated.
  • the US A-5,885,581 describes such a gel-like product which is 20-30 Weight percent polyethylene glycol 200, 0.005-0.03 weight percent Preservative, 0.05-0.2% by weight sorbic acid, 0.5-2 Weight percent allantoin, 1-3 weight percent xanthan and optional Perfumes and which is characterized by 5-15 Percent by weight of a liquid onion extract (Allium Cepa extract) on which Base of an aqueous carrier in an amount of about 55-65% by weight.
  • the product thus represents a fat (oil) - free gel and is externally on damaged skin tissue, especially scarred tissue applied.
  • the Product is further characterized by a pH of 4.5-5.5 and a Particle size of less than 50 ⁇ m.
  • Hirudoid®forte a gel which contains as active ingredient mucopolysaccharide polysulphuric acid ester (445 mg, corresponding to 40,000 units in 100 g of ointment).
  • Other ingredients include the components required for gel manufacture, such as isopropyl alcohol, polyacrylic acid, propylene glycol, and water.
  • Mucopolysaccharide polysulfuric acid esters generally have a heparinoid effect and therefore correspond to the aforementioned Kelofibrase® product.
  • Hirudoid®forte ointment is known, in addition to the above-known drugs a mixture of mono- and diglycerides of higher fatty acids and medium chain triglycerides, etc., and isopropyl alcohol, imide urea, phenoxyethanol and water.
  • Such products are useful for treating phlebopathies, near-surface phlebitis, hematomas, and for loosening hard scars.
  • the product must not be applied to injured skin.
  • Hylaform® is known as a gel implant containing cross-linked hyaluronic acid which is present in an aqueous saline solution for injection. With such an agent skin deformations should be treatable.
  • a liquidum which contains horse chestnut dry extract and chamomile flower dry extract in 1,3-butanediol, dexpanthenol, allantoin and odoriferous substances.
  • This agent should be used in the treatment of skin damage such as wound blister sensitive pressure points and scars by orthopedic apparatus, and bedsores. An indication for scars by surgery or other Skin damage is not specified here.
  • the ointment Striatridin® contains in addition to the ointment base as the active ingredient alkyl branched fatty acid esters of octadecyl alcohol, amino acid sol and ethyl nicotinate.
  • DE-A 196 28 284 describes the use of wild garlic for the treatment of psoriasis.
  • DE-A 37 23 248 relates to the use of thiosulfinic acid derivatives for the treatment of inflammation. These can be obtained, inter alia, by extraction of onions and subsequent chromatography. Onion extract itself is not used here.
  • EP-B 429 080 relates to a preparation process for S-allylcysteine-containing products, wherein z. For example, aqueous garlic extracts are added with cysteine to produce S-allylcysteine.
  • EP-B 364 442 relates to an oil extract of at least 3 different herbs selected from spurge, veronica, yarrow, fumitory, garlic, nettle and marigold. This combination is used as an oil, eg with paraffin against psoriasis.
  • EP-B EP 201 956 relates to the extraction and chromatographic fractionation of eg tobacco, algae, garlic, wherein the specific substances obtained are to be used as antioxidant substances in cosmetics.
  • EP-A-0273407, WO98 / 50054 and US-A-5885581 disclose hydrogels containing onion extracts.
  • US-A-6,200,570 relates to compositions containing garlic extract and at least one other plant extract such as aloe vera and anti-inflammatory agents such as diclofenac having anti-allergic analgesic activity
  • JP-A 2000327535 describes a hair tonic comprising, for example, Allium schoenoprasum and / or other plant extracts.
  • JP-A 09194334 relates to a hair loss effective hair tonic, z.
  • JP-A 08012570 and JP-A 0317413 relate to plant extracts such as Allium sativum or Allium victorialis containing anti-allergenic or anti-dandruff agents.
  • the products which can be used for scar treatment are either in the form of a gel or, if they are not in the form of a gel, contain active substances which can bring about considerable side effects.
  • the estradiol containing product is application limited in terms of hormone content. Mucopolysaccharide polysulphuric acid esters with their heparinoid effect can trigger hypersensitivity reactions and must never be applied to injured skin.
  • the above-mentioned Hylaform®-hyaluronic acid-containing product is an implant which can only be suitable for the mechanical correction of skin deformations and insofar brings no lasting effect on the skin tissue itself.
  • the Liquidum PC 30 V is only used for printing block scars treatment of small scale, as caused for example by orthopedic apparatus, and thus far not described for permanent change damaged skin tissue through surgery, injury, burns.
  • Object of the present invention is therefore to provide a product which having a well-tolerated active ingredient and wherein this in a Emulsion base is incorporated, whereby the skin is not dried out and moreover a positive, nurturing, in particular elasticity-promoting skin care effect can be achieved.
  • an agent for topical application which has an onion extract as active ingredient and, in addition to the customary additives selected from bodying agents, dyes, antioxidants, perfumes, humectants, preservatives, stabilizers, additives, has a fat (oil) phase , Preference may additionally be given to a water phase and corresponding emulsifiers selected from the group of O / W and / or W / O emulsifiers or mixtures thereof or with suitable coemulsifiers.
  • compositions may have a total of 5-99% fat (oil) phase, 0.1-35% additives, 1-20% onion extract and the remaining substances, if present, in the amounts indicated below.
  • Particularly suitable are agents which are composed of 70-99, especially 80-98% fat (oil) phase, 0.1-20%, especially 0.1-10%, additives and 1-20%, preferably 1- Contain 10% and more particularly 2-5%, onion extract, wherein preferably may be present as the remainder of solvent, such as.
  • alcohols ethanol, isopropanol
  • the agent according to the invention is furthermore preferably composed of a fat (oil) phase in an amount of 5-70%, 0.1-15% emulsifier (O / W; W / O); Mixtures thereof or with co-emulsifiers, 0.1- 35% additives, 1-20% onion extract and the remainder water or a water / alcohol z.
  • emulsifier O / W; W / O
  • Mixtures thereof or with co-emulsifiers, 0.1- 35% additives, 1-20% onion extract and the remainder water or a water / alcohol z As ethanol, isopropanol, mixtures, for example up to 20%.
  • the fat (oil) phase 5-60%, preferably 5-40% and most preferably 5-25%.
  • the onion extract is especially a water or alcohol or water alcohol containing onion extract.
  • the To incorporate onion extract into a fat (oil) containing phase so that this one uniform distribution of the extract is stable and beyond means this basis a drying out of the treated skin can not take place and thus a nourishing, elasticity-promoting effect is achieved, so that the treatment of damaged skin parts, both in terms of scarring or relaxation as well as with respect to skin softness positively influenced or can be prevented.
  • composition according to the invention between 1-15%, 2-15%, especially 5-15% of the onion extract, based on the total amount, preferably 5-10, especially 8-10% and most preferably 2-4% or 10 %.
  • the additives are preferably present at 0.1-30, in particular 0.1-25% depending on the application.
  • the amount of emulsifiers is in particular 0.1-10%, in particular 1-10%, preferably 1-8% and very particularly 1-5%.
  • the onion extract is especially an aqueous ethanolic extract. It preferably has water and 10-15% ethanol. It may also be beneficial to use an alcoholic onion extract. This may, in addition to alcohol, preferably also 10-80%, in particular 20-60% of a solvent selected from triglycerides, hydrocarbons and fatty acid esters. The quantities are by weight%, unless stated otherwise.
  • the fat (oil) phase is preferably selected from hydrocarbons, fatty alcohols, ethers and esters, (poly) olfettklam, triglycerides, natural oils, natural fats, waxes, silicone oils, silicone waxes or mixtures thereof.
  • liquid paraffins, lactic acid esters, fatty alcohol ethers, evening primrose oil, silicone oil or mixtures thereof are preferred here.
  • the W / O emulsifier advantageously has an HLB value of 1-9, in particular 1-8, preferably 2-7 and very particularly preferably 3-6 and the O / W emulsifier has an HLB value of 9-18, preferably 9-15 and in particular 9-13, or is an ionic O / W emulsifier.
  • w / o emulsifiers are sorbitan derivatives, polyethoxylated fatty acids / alcohols / esters /, triglycerides, (poly) glyceryl derivatives, polyol esters, glucose derivatives, pentaerythritol derivatives, alkylphenols, (block) polymers, fatty acid salts, siloxanes or mixtures hereof and more particularly Abil® EM 90, Arlacel®582 and magnesium stearate or mixtures thereof. It may also be present co-emulsifiers, such as Arlatone®T (V).
  • V Arlatone®T
  • O / W emulsifier are polyoxyethylated products, nonionic and ionic phosphates, ionic monovalent salts, (poly) glyceryl esters, sugar esters, sterol derivatives, castor oil derivatives, siloxanes or mixtures thereof or mixtures with coemulsifiers thereof.
  • Tego Care® 450, Eumulgin® B1 or mixtures thereof and / or with coemulsifiers are suitable here.
  • Stabilizers selected from acrylamides, acrylates and polysaccharides, in particular those as described below.
  • agents according to the invention furthermore as additives, those selected from vitamins, electrolytes, such as.
  • vitamins, electrolytes such as.
  • magnesium sulfate or sodium chloride allantoin, D-panthenol, hyaluronic acid, mucopolysaccharides, dyes, perfumes, preservatives, moisturizers have.
  • wax products as well as or alternatively as an additive may furthermore additionally contain lecitins, in particular Phosal® 50 SA.
  • the agent may contain varying amounts of water, fat phase, emulsifier, additives and active ingredient (onion extract).
  • a lotion, a fluid, a cream or a balm / ointment are obtained.
  • the agent may thus preferably be composed of a fat (oil) phase in an amount of 5-70% by weight, in particular 5-55%, one or more W / O emulsifiers, mixtures thereof or with co-emulsifiers in a total amount from 0.5 to 15%, in particular from 0.5 to 10%, and also from 0.1 to 25%, in particular from 0.1 to 22%, of additives of the abovementioned type, and from 1 to 15, in particular from 1 to 10% of above-mentioned onion extract and the remainder water or a mixture of water with alcohols such as ethanol, isopropanol in amounts up to 20%.
  • a fat (oil) phase in an amount of 5-70% by weight, in particular 5-55%
  • one or more W / O emulsifiers, mixtures thereof or with co-emulsifiers in a total amount from 0.5 to 15%, in particular from 0.5 to 10%, and also from 0.1 to 25%, in particular from 0.1 to 22%, of additives of the abovementi
  • the agent may in particular also be composed of 5-40%, in particular 5-30%, fat (oil) phase, 0.1- 15%, in particular 1-10% of one or more O / W emulsifiers or mixtures thereof or with Co-emulsifiers, 0.1-32%, especially 0.1-20% additives and 1-10% onion extract and the remainder water or a mixture of water with alcohols such as ethanol, isopropanol in amounts up to 20%.
  • the means for the treatment of scars or of damaged and / or sagging skin tissue in particular as e.g. Massage oil or balm, lotion, fluid or cream are made.
  • W / O emulsifiers in particular lotions
  • Particularly suitable is a O / W cream of the type described above for the treatment of e.g. of acne scars.
  • a lotion is recommended preferred in the treatment or for the preventive prevention of Stretch marks or generally sagging skin is used.
  • balm that is especially suitable for Treatment of surgical or burn scars, incisions suitable is.
  • Massage oil is particularly suitable for prevention or care and Treatment of larger areas of skin such as in case of pregnancy stiffness.
  • the dosage form is not limited to a specific indication and can be varied.
  • an onion extract is particularly suitable a water, alcohol or water-alcohol containing extract of dried onions.
  • the extraction can be carried out with water itself or with alcohol, optionally with the addition of solvents as mentioned below, or a mixture of water and one or more alcohols, as mentioned below.
  • the dried onions also known as dried onion chips obtained from the parent plant Allium cepa Linne, can be extracted first with the extractant by the percolating the drug preferably in the heat, for example at 40-90 ° C, exhaustively.
  • the percolate can then be evaporated at a suitable, in particular elevated temperature above 30 ° C under vacuum to Spissum extract (thickened extract) and then dissolved in the desired solvent to the water, alcohol or water-alcohol mixture - fluid extract.
  • the fluid extract may also be obtained without prior evaporation by direct reaction with the desired solvent.
  • a reddish-brown to brown liquid with a characteristic odor is obtained.
  • the ratio of dry drug to fluid extract may vary from 0.1: 1 to 10: 1, preferably 0.1: 1 to 5: 1, in particular 0.15: 1 to 4: 1. Most preferred ratios are 0.16: 1 or 4: 1.
  • Particularly preferred are fluid extracts of the type mentioned with water / alcohol mixture or only alcohol as solvent.
  • the mixture preferably contains 5-60%, in particular 10-50% and very particularly 10-40% or else 10-15, especially 13%, alcohol, preferably ethanol.
  • the alcohol is preferably selected from ethanol, isopropanol or propanol or dihydric alcohols such as butylene glycol, propylene glycol or mixtures thereof. Particularly preferred is ethanol. It may also be advantageous if the onion extract, which is extracted with water or other such as the abovementioned alcoholic solvents, to the alcoholic fluid extract as described, worked up. In particular, in this case 10-80%, preferably 20-60% of the alcohol can be replaced by a solvent selected from the substances mentioned below under point II, in particular hydrocarbons, triglycerides, especially medium-chain, and fatty acid esters or mixtures thereof.
  • An onion extract which can be used according to the invention can be prepared, for example, as follows:
  • the dried onions, also called onion chips can eg be extracted with purified water eg in the ratio of drug to extractant (water) of 1:16.
  • the ratio of dry drug to native extract then corresponds to 1.8: 1, or 1.5-2.2: 1 respectively.
  • the ratio of dry drug to fluid extract is then 0.16: 1.
  • the drug eg 16kg chips
  • the percolate can then be evaporated at about 55 degrees Celsius under vacuum to spissum extract (concentrated extract). It is heated for a short time (eg 3 seconds at 141 degrees Celsius).
  • the resulting spissum extract is viscous and is dissolved in water, alcohol or in the water-alcohol mixture to Fluidex Exercise zBog ratio. A reddish-brown to brown liquid with a characteristic odor is obtained.
  • This extract is miscible with water in any ratio, has a relative density at 20 degrees Celsius of 1.00-1.03 g / ml. If worked with water / alcohol, especially ethanol, for example, about 13-20% (v / v) alcohol (eg ethanol) may be present.
  • the dry residue (after 2 hours at 105 degrees Celsius) is at least 7.0% (m / m). With regard to the microbiological purity, the product meets the requirements of category 3 of the DAB 10.
  • the characteristic ingredients of onions are derivatives of sulfur-containing amino acids. In addition, protein, fat and carbohydrates are still present.
  • a water-alcohol onion extract is preferably used in the compositions according to the invention, in particular a water-ethanol extract as described above, preferably with 10-40, in particular 13-20%, in particular 10-15% ethanol content.
  • the onion extract may contain other solvents, in particular glycol, butylene glycol, propylene glycol, instead of ethanol.
  • an alcohol, preferably ethanol-containing extract which, in particular, as mentioned above, may also contain further solvents, for example 10-80%, in particular 20-60%, as may be mentioned under point II .
  • a water-alcohol in particular ethanol-onion extract
  • an alcoholic especially ethanolic onion extract with 10-80%, in particular 20-60%
  • solvents such as those mentioned under point II , especially here hydrocarbons, triglycerides z.
  • the ratio of water / alcohol and alcohol / solvent onion extract can be in particular 3: 1 to 1: 3, preferably 1: 1.
  • Particularly preferred oil components are liquid paraffins, fatty acid esters such as isopropyl palmitate or myristate, fatty alcohol ethers such as dicaprylyl ether (Cetiol®OE) and the natural fats and oils mentioned, in particular avocado, soybean, peach kernel, apricot kernel oil and especially evening primrose oil, in particular Mixtures thereof, silicone oils of the type described above and lactic acid esters, for example Cosmacol® ELI and mixtures thereof with the abovementioned components.
  • fatty acid esters such as isopropyl palmitate or myristate
  • fatty alcohol ethers such as dicaprylyl ether (Cetiol®OE)
  • the natural fats and oils mentioned in particular avocado, soybean, peach kernel, apricot kernel oil and especially evening primrose oil, in particular Mixtures thereof, silicone oils of the type described above and lactic acid esters, for example Cosmacol® ELI and mixtures thereof with the abovementioned components.
  • liquid paraffins lactic acid esters, fatty alcohol ethers, evening primrose oil and silicone oils
  • silicone waxes are particularly suitable, especially combinations thereof and also with the aforementioned paraffins, lactic acid esters and evening primrose oil.
  • O / W emulsifiers are in particular those with an HLB value of 9- 18, preferably 9-15 and especially 9-13 suitable.
  • polyoxyethylated products such as (HLB values on the right): G - 2111 Polyoxyethylene oxypropylene oleate 9.0 G - 2125 Tetrathylenglykolmonolaurat 9.4 Brij® 30 polyoxyethylene 9.5 Tween® 61 polyoxyethylene 9.6 Tween® 81 polyoxyethylene 10.0 G - 3806 polyoxyethylene 10.3 Tween® 65 polyoxyethylene sorbitan 10.5 Tween® 85 polyoxyethylene 11.0 G - 3910 Polyoxyethylenoleyether 12.2 G - 2127 polyoxyethylene monolaurate 12.8 Renex® 690 polyoxyethylene alkylaryl 13.0 Polyethylene glycol 400 monolaurate 13.1 Cremophor® EL Polyoxyethylene castor oil 13.3 G - 1284 Polyoxyethylene castor oil 13.3 Tween® 21 polyoxyethylene 13.3 Renex® 20 Polyoxyethylene ester mixed fat 'and resin acids 13.5 G - 1441 Polyoxyethylene sorbitol -
  • Myrj® 45 polyoxyethylene glycol monostearate 11.2
  • sugar esters such as glucose esters e.g.
  • ionic emulsifiers monovalent salts of, for example, fatty acids or fatty alcohol sulfates can be used here, for example sodium stearate or triethanolamine stearate, Lanette® E (sodium cetearyl sulfates) or phosphates such as Amphisol® K (potassium cetyl phosphate) or glutamates, eg Hostapon® CCG (sodium cocoyl glutamate ) or lactylates, eg Crolactil® SSL (Sodium Stearoyl Lactylate).
  • Lanette® E sodium cetearyl sulfates
  • phosphates such as Amphisol® K (potassium cetyl phosphate) or glutamates, eg Hostapon® CCG (sodium cocoyl glutamate ) or lactylates, eg Crolactil® SSL (Sodium Stearoyl Lactylate).
  • emulsifiers can also be used in mixtures with coemulsifiers, which can also be used generally as consistency regulator.
  • coemulsifiers can be selected from the group of fatty alcohols such as Stearyl Alcohol (Lanette® 18), Cetyl Alcohol (Lanette® 16), Myristyl Alcohol (Lanette® 14) or Cetearyl Alcohol (Lanette® O).
  • fatty acids for example stearic acid or glyceryl esters, such as glyceryl stearate, in particular glycerol monostearate or glycerol distearate, or mixtures thereof, eg Tegin® M.
  • waxes can also be used as bodying agents, for example beeswax (Lunacera® alba), Kester® wax K82H (C 20-40 -alkyl stearate) or Lunacera® M (micro wax) or hydrocarbon waxes such as Lunacera® P (mineral wax) and hydrogenated castor oil (Cutina® HR) or synthetic waxes such as cetyl palmitate (Cutina® CP) or myristyl myristate (Crodamol® MM), or stearyl stearates (Crodamol® SS).
  • beeswax Liunacera® alba
  • Kester® wax K82H C 20-40 -alkyl stearate
  • Lunacera® M micro wax
  • hydrocarbon waxes such as Lunacera® P (mineral wax) and hydrogenated castor oil (Cutina® HR)
  • synthetic waxes such as cetyl palmitate (Cutina® CP) or
  • vitamins such as tocopherol acetate (vitamin E) or vitamin A, for example as retinol palmitate can be selected as additional active ingredients.
  • electrolytes such as magnesium sulfate or sodium chloride (electrolytes eg in amounts of 0.2-2%) are suitable.
  • polysaccharides such as glycosaminoglycans, in particular mucopolysaccharides.
  • non-heparinoid compounds such as chondroitin sulfate or dermatan sulfate or keratan sulfate or heparinoid compounds such as heparin, in particular their salts, for example sodium salts.
  • allantoin, D-panthenol, hyaluronic acid and / or zinc derivatives such as Zincidone® (zinc PCA), zinc gluconate or zinc oxide are particularly suitable.
  • the amounts of individual additional active ingredients vary and may be, for example, in each case 0.01% -20% or 0.1-6%, in particular 1-5% or 3-5%.
  • vesicle-forming agents, in particular lecithins and analogs thereof are suitable as additives.
  • phospholipids such as lecithin (egg or soya lecithin), eg Phosal® 50 SA (about 50% soy lecithin), phosphatidyl choline, serine or Diethanolamine and mixtures thereof.
  • lecithin-analogous components are sphingolipids (eg ceramides, cerebrosides, sphingosine, sphingomyelin), phytosterols (essentially mixtures of ⁇ -sitosterol, campesterol and stigmasterol) and derivatives thereof, in particular ethoxylates such as Generol® 122 E 5 (PEG-5 soy bean Sterol), Gererol® R E5 (PEG-5 Rapeseed Sterol).
  • sphingolipids eg ceramides, cerebrosides, sphingosine, sphingomyelin
  • phytosterols essentially mixtures of ⁇ -sitosterol, campesterol and stigmasterol
  • ethoxylates such as Generol® 122 E 5 (PEG-5 soy bean Sterol), Gererol® R E5 (PEG-5 Rapeseed Sterol).
  • vesicle are polyethoxylated fatty alcohols and fatty acids having preferably 1-4 EO with an HLB value of 2 to 6 wherein the lipophilic group preferably consists of C 16 to C 18 alkyl chains, Polyglycerolalkylether, Glucosyldialkylether, sucrose diesters, Kollagenhydrolysatester, quaternary ammonium compounds and poloxamers.
  • Phosal® 50 SA is particularly preferred here.
  • astringent and sebum-regulating substances can be used, such as Acnacidol.RTM. 101 (propylene glycol, hydroxydecanoic acid), Asebiol.RTM. BT (hydrolyzed yeast protein, pyridoxines, niacinamides, glycerol, panthenol, propylene glycol, allantoin, biotin), Lipacide.RTM.
  • C8C0 caproyl collagen Aminoacids
  • Sebosoft® glycerol, aqua, PEG-8, caprylyl glycol, sebacic acid, sodium polyacrylate
  • Sepi Control® A5 capryloylglycine, methylglycine, cinnamonum zeylanicum.
  • plant extracts may be contained, eg birch leaf extract, aloe vera extract, marigold, hibiscus, burdock root, hamametis, Wassernabelkraut-, algae, quince, water lily, cinnamon extract.
  • Cooling / soothing agents such as Frescolat® ML (Menthyl Lactate) or Eashave® (Sodium Hyaluronate, Wheat Germ Extract, Saccharomyces Cerevisiae Extract) may also be incorporated.
  • circulation-promoting substances for example nicotinic acid derivatives such as methyl or tocopheryl nicotinate, alpha- and betahydroxy acids and their derivatives, for example glycolic, malic, citric, tartaric, salicylic, isopropylbenzyl salicylates, C12-13 alkyl lactates (Cosmacol® ELI) or also antiphlogistic and antibacterial substances such as triterpenes, eg ursolic acid, glycyrrhizic acid or glycyrrhetinic acid and their derivatives, eg stearyl glycyrrhetinates, potassium glycyrrhinate; Pantothenic acid
  • antioxidant and cell protecting substances such as flavonoids, such as rutin, ferulic acid and their esters or isoflavones such as soy isoflavones or coenzyme Q 10 can be used as effective additives.
  • flavonoids such as rutin, ferulic acid and their esters
  • isoflavones such as soy isoflavones or coenzyme Q 10
  • additional active substance combinations from a) -f) or a) -i) or a) + c) -i).
  • antioxidants may preferably be selected from butylhydroxytoluene, butylhydroxyanisole, ascorbyl palmitate, tocopherol, possibly in combination with synergists as in Controx® VP (tocopherol, lecithin, ascorbyl palmitate, hydrogenated palm glycerides citrate), gallic acid alkyl esters such as octyl, dodecyl and cetyl gallate or Combinations thereof.
  • Perfumes are especially selected from essential oils.
  • commercial perfume compositions are possible such as perfume oil Deliana.
  • Essential oils which are suitable for the compositions according to the invention are in particular the essential oils selected from rosemary oil, orange oil, lavender oil, lime oil, cinnamon oil, geranium oil, cedarwood oil, rosewood oil, valerian oil, ylang-ylang oil, citronella oil, tea tree oil, manuka oil, eucalyptus oil, mint oil , Lemongrass oil, cypress oil, niaouli oil, pine needle oil, pine oil, camphor, menthol. These additives can also be considered as additional active ingredients. These include then also essential unsaturated fatty acids and their esters, for example linoleic or linolenic acid, glyceryl linoleates, glyceryl linolenates are used.
  • octyl or isoamyl p-methoxycinnamates Especially preferred are octyl or isoamyl p-methoxycinnamates, octocrylenes, 4-methylbenzylidene camphor, homosalates and / or butyl methoxydibenzoylmethanes and / or benzophenones-3.
  • inorganic UV filters such as zinc oxide and titanium dioxide, in particular micronized and / or coated, for example Z-Cote®, Tioveil®.
  • Preservatives include iodopropynyl butylcarbamate, DMDM hydantoin, phenoxyethanol and other common preservatives such as sorbic and dehydroacetic acid and its salts, methyldibromoglutanonitrile, etc. or combinations thereof, or other acids such as benzoic or salicylic acid, or benzyl alcohol or esters such as p-hydroxy benzoic acid esters, for example methyl, ethyl, propyl, butyl, iso-butylparaben, preferably methyl or propylparaben or mixtures thereof or climbazole or suitable combinations of said substances such as methyl, propylparaben and sorbic acid in question.
  • moisturizers such as polyhydric alcohols such as polyethylene glycol, propylene glycol, butylene glycol, sorbitol, glycerol or polymers, eg Polyquaternium types such as Polyquaternium -39 (Merquat® plus 3330), proteins such as collagen or its hydrolysates, amino acids, urea, D-panthenol, vegetable Proteins such as from wheat, soy or almond or their hydrolysates, eg Tritisol® (Hydrolyzed Wheat Protein), polysaccharides such as Fucogel® 1000 (biosaccharides Gum-1), glucosaminoglycans, eg hyaluronic acid or sulfated glycosaminoglycans such as chondroitin sulfate, dermat
  • polyethylene / propylene glycol or glycerol in amounts of, for example, 0.5-10%, in particular 2-5%, and also polysaccharide compounds such as Fucogel® 1000.
  • stabilizers are suitable for a wax products such.
  • Amerchol® CAB consisting of petrolatum and lanolin can also be used as stabilizers.
  • stabilizers which can be used are components for pH regulation, such as NaOH (eg 5% strength, eg in amounts of 0.1-4%, in particular 1-3%) or acids such as citric acid, lactic acid or malic acid or EDTA-Na in an appropriate amount as a complexing agent.
  • NaOH eg 5% strength, eg in amounts of 0.1-4%, in particular 1-3%)
  • acids such as citric acid, lactic acid or malic acid or EDTA-Na in an appropriate amount as a complexing agent.
  • the amount and type of pH regulators depends on the other additives and are familiar to the person skilled in the art.
  • suitable stabilizer is a combination of one or more acrylamides, one or more acrylates and one or more polysaccharides, in particular starch or starch derivatives, each component being present in an amount of 0.05-8%, preferably 0.1 -5% can be included.
  • Particularly preferred acrylamides are polyacrylamide, eg Flocare® T 920 GC or polyacrylamide-containing mixtures such as Sepigel® 305 (polyacrylamides, C13-14 isoparaffin, laureth-7), Sepigel® 501 (acrylamide copolymer, mineral oil, C13-14 isoparaffin, polysorbate 85) , Sepigel® 502 (C13-14 isoparaffin, isostearyl isostearates, sodium polyacrylates, polyacrylamides, polysorbate 20), Creagel® DC DC (polyacrylamides, polydecenes, dimethicone copolyol), Creagel® EZ 5 (polyacrylamides, polydecenes, laureth-5).
  • Sepigel® 305 polyacrylamides, C13-14 isoparaffin, laureth-7
  • Sepigel® 501 acrylamide copolymer, mineral oil, C13-14 isoparaffin, polysorbate 85
  • Sepigel® 502 C13-14 iso
  • the acrylates used are high molecular weight (1 to 3 million) carboxy-vinyl copolymers and their copolymers, especially after neutralization by alkali.
  • acrylate copolymers for example arylates / C10-30 alkyl acrylate crosspolymer, known as Carbopol® 1342, 1382, ETD 2020, Pemulen® TR-1, TR-2.
  • starch or starch derivatives in particular the following substances are suitable: rice, wheat, corn and potato starch.
  • hydrophobically modified starches such as aluminum Starch Octenylsuccinate (Dry Flo® PC, Fluidamid® DF 12) or mixtures thereof, such as Natrasorb® HFB (Aluminum Starch Octenylsuccinate, Acrylates Copolymer, Magnesium Carbonate), ASO / MM3® (Aluminum Starch Octenylsuccinate, Magnesium Myristates), Dry Flo® Elite LL (Aluminum Starch Octenylsuccinate, Lauroyl Lysine), Facemat® (Aluminum Starch Octenylsuccinate, Mica, Zea Mays (Com) Starch, Silica, Titanium Dioxide, Zinc Oxide). Very particular preference is given to Dry Flo® PC and Natrasorb® HFB.
  • Al Starch Octenylsuccinate Dry Flo® PC, Fluidamid® DF 12
  • Natrasorb® HFB Al Starch Octenylsuccinate, Acrylates Copoly
  • the abovementioned combination of stabilizers can also be used in particular when using O / W emulsifiers. Particular preference is given here to Sepigel®305 or 501, PNC®410 / 400 or Carbopol®ETD2020 and Dry Flo®PC or Natrasorb®HFB, in particular combinations thereof.
  • additives or active ingredients may vary within the ranges indicated.
  • additives selected from additives such as vitamins, electrolytes such as magnesium sulfate and sodium chloride, allantoin, D-panthenol, hyaluronic acid, mucopolysaccharides such as heparinoids and non-heparinoids and mixtures thereof, as well as perfumes, preservatives and humectants. These may preferably be combined with waxes and / or lecithins such as in particular Phosal®50SA.
  • the onion extract-containing agent described can be prepared by combining onion extract, preferably with soluble there additives, then preparing the fatty phase, preferably there soluble additives can be incorporated, and then prepares the water phase, which there preferably soluble additives and especially alcohols of The above-mentioned type and amount, and then the water and the fat phase at temperatures of 60 to 90 ° C together with one or more emulsifiers or mixtures thereof or emulsified with co-emulsifiers, optionally homogenized and after cooling (eg at 20- 50 ° C), the additives, if any, added and worked up in a suitable manner, eg by homogenization.
  • the onion extract can be incorporated into the fat (oil) phase together with the additives, it also being possible to add solvents, in particular alcohols of the abovementioned type and amount.
  • solvents in particular alcohols of the abovementioned type and amount.
  • An agent prepared as described above is particularly suitable, for example, as a dermatological composition for the care, treatment or prevention of damaged skin tissue, in particular scar tissue, or sagging tissue such as stretch marks, or of damaged skin tissue, which may have arisen due to cuts, surgical wounds, burns or by age-related degeneration.
  • the damaged skin tissue shows after a short time an improvement of the scarred or damaged parts and can be obtained by the new oil phase-containing formulation beyond even much softer, supple and elastic than without this nourishing, skin-regenerating additive.
  • the agent can be surprisingly used with extremely regenerative success even in scars after cosmetic surgery or for the treatment of acne scars.
  • Examples 1-6 an aqueous-ethanolic onion extract, in particular with a proportion of 13-20% ethanol and in Examples 7,8, an alcohol-containing, namely ethanol and medium chain triglyceride (about 60%) containing onion extract was used.
  • Examples 9, 10 the efficacy is shown on the basis of medical application observations.
  • Cuts (45), abrasions (14), surgical wounds (240), burn scars (18), acne scars (6), or other scars (15) in the head and neck were reported in 338 patients (62% female) averaging age 41 years (65), arms (135), legs (84), on the upper body / chest (27), upper body / back (14) or other places (54) over a period of ⁇ 1 month (106) to 3 months (117) or> 3 months available. These patients were treated for a period of up to 6 months with a product according to this Example 1 by applying to the affected area of skin on average twice a day. Prior to treatment, in about 15% of cases, use of known products such as onion extract gel (Contractubex) or ketofibrase had been made without further success.
  • Contractubex onion extract gel
  • ketofibrase had been made without further success.
  • the product according to the invention is therefore extremely well suited for the effective prevention or reduction of stretch marks, which clearly results from the evaluation values given in Table 2 (criteria analogous to Example 9).
  • Development stripes Assessment doctor Assessment patient a) Very good 53.0% 51.1% b) good 39.0% 40.1% c) moderate 7.0% 6.0% d) bad 1.0% 2.3% Overall judgment a) + b) 92.0% 91.1% Hautver cleansekelt: Assessment doctor Assessment patient a) very good 69.6% 75.7% b) good 28.1% 22.9% c) moderate 0.9% 0.9% Overall judgment a) + b) 97.7% 98.6%

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Edible Oils And Fats (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (30)

  1. Agent contenant un extrait d'oignon à usage local, caractérisé en ce qu'il contient une phase grasse (huileuse), des additifs choisis parmi des agents de consistance, des colorants, des substances parfumées, des agents humectants, des antioxydants, des conservateurs, des stabilisateurs, des substances actives ajoutées, ainsi qu'un extrait d'oignon.
  2. Agent selon la revendication 1, caractérisé en ce qu'il présente de 70 à 99% de phase grasse (huileuse), de 0,1 à 20% d'additifs et de 1 à 20% d'extrait d'oignon.
  3. Agent selon la revendication 1, caractérisé en ce qu'il contient une phase grasse (huileuse), des additifs choisis parmi des agents de consistance, des colorants, des substances parfumées, des agents humectants, des antioxydants, des conservateurs, des stabilisateurs, des substances actives ajoutées et un extrait d'oignon ainsi également qu'une phase aqueuse et un ou plusieurs émulsifiants E/H ou H/E ou leurs mélanges ou des mélanges avec des co-émulsifiants.
  4. Agent selon l'une des revendications 1 à 3, caractérisé en ce que l'extrait d'oignon est un extrait d'oignon contenant de l'eau, de l'alcool ou de l'eau/alcool.
  5. Agent selon la revendication 3 ou la revendication 4, caractérisé en ce qu'il contient de 5 à 70% de phase grasse (huileuse), de 0,1 à 15% d'émulsifiants E/H ou H/E ou leurs mélanges ou des mélanges avec des co-émulsifiants, de 1 à 20% d'extrait d'oignon, de 0,1 à 35% d'additifs et pour le reste de l'eau ou un mélange d'eau/alcool.
  6. Agent selon l'une des revendications 3 à 5, caractérisé en ce qu'il présente une phase grasse (huileuse) en une quantité de 5 à 70%, un ou plusieurs émulsifiants E/H en une quantité totale de 0,5 à 15%, ainsi que leurs mélanges ou des mélanges avec des co-émulsifiants, ainsi que de 0,5 à 25% d'additifs, de 1 à 15% d'extrait d'oignon et pour le reste de l'eau ou un mélange d'eau/alcool.
  7. Agent selon la revendication 6, caractérisé en ce qu'il présente de 5 à 55% de phase huileuse, de 0,5 à 10% d'un ou plusieurs émulsifiants E/H ou leurs mélanges ou des mélanges avec des co-émulsifiants, de 0,1 à 25% d'additifs, de 1 à 10% d'extrait d'oignon et pour le reste de l'eau ou un mélange d'eau/alcool.
  8. Agent selon l'une des revendications 3 à 5, caractérisé en ce qu'il présente de 5 à 40% de phase grasse (huileuse), de 0,1 à 15% d'un ou plusieurs émulsifiants H/E ou des mélanges de ceux-ci avec des co-émulsifiants, de 0,1 à 32% d'additifs, de 1 à 10% d'extrait d'oignon et pour le reste de l'eau.
  9. Agent selon l'une des revendications 1 à 8, caractérisé en ce que l'extrait d'oignon qu'il contient est un extrait à l'éthanol aqueux.
  10. Agent selon la revendication 9, caractérisé en ce que l'extrait d'oignon contient de l'eau et de 10 à 40% d'éthanol.
  11. Agent selon l'une des revendications 1 à 8, caractérisé en ce que l'extrait d'oignon qu'il contient est un extrait alcoolique qui présente de 10 à 80% d'un solvant choisi parmi des esters d'acides gras, des triglycérides, des hydrocarbures ou des mélanges de ceux-ci.
  12. Agent selon l'une des revendications 1 à 8, caractérisé en ce que l'extrait d'oignon est un mélange d'un extrait d'oignon à l'eau/éthanol avec 10 à 40% d'éthanol et d'un extrait alcoolique d'oignon avec 10 à 80% d'un solvant choisi parmi des esters d'acides gras, des triglycérides, des hydrocarbures ou des mélanges de ceux-ci.
  13. Agent selon l'une des revendications 1 à 12, caractérisé en ce que la phase huileuse (grasse) est choisie parmi des hydrocarbures, des alcools gras, des éthers ou esters d'alcools gras, des esters d'acides gras avec des polyols, des triglycérides, des huiles naturelles, des matières grasses naturelles, des cires, des huiles de silicone, des cires de silicone ou des mélanges de ces substances.
  14. Agent selon l'une des revendications 1 à 13, caractérisé en ce qu'il présente comme phase huileuse des paraffines liquides, des esters de l'acide lactique, des éthers d'alcools gras, de l'huile de carthame, de l'huile de silicone ou des mélanges de ces substances.
  15. Agent selon l'une des revendications 3 à 14, caractérisé en ce que l'émulsifiant E/H présente une valeur d'équilibre hydrophile/lipophile HLB de 1 à 8 et en ce que l'émulsifiant H/E présente une valeur HLB de 9 à 18 ou est un émulsifiant H/E ionique.
  16. Agent selon l'une des revendications 3 à 7 ou 9 à 15, caractérisé en ce qu'il contient comme émulsifiant des dérivés de sorbitane, des acides/alcools/esters gras/triglycérides polyéthoxylés, des dérivés de (poly)glycéryle, des esters de polyols, des dérivés de glucose, des dérivés de pentaérythritol, des alkylphénols, des polymères (séquencés), des siloxanes, des sels d'acides gras ou des mélanges de ces substances.
  17. Agent selon l'une des revendications 3 à 7 ou 9 à 16, caractérisé en ce qu'il présente comme émulsifiant de l'Abil® EM 90, de l'Arlacel® 582 et du stéarate de magnésium ou des mélanges de ces substances.
  18. Agent selon l'une des revendications 3 à 5 ou 8 à 15, caractérisé en ce que l'émulsifiant est choisi parmi des produits polyéthoxylés, des phosphates non ioniques et ioniques, des sels monovalents ioniques, des esters de (poly)glycéryle, des esters de sucres, des dérivés de stérols, des dérivés de l'huile de ricin, des siloxanes ou leurs mélanges ou des mélanges de ces substances avec des co-émulsifiants.
  19. Agent selon la revendication 18, caractérisé en ce qu'il contient comme émulsifiant du Tego Care® 450, de l'Eumulgin® B1 ou des mélanges de ceux-ci.
  20. Agent selon l'une des revendications 3 à 5, 8 à 16 ou 18, 19, caractérisé en ce que le stabilisateur utilisé est un mélange d'acrylamides, d'acrylates et de polysaccharides.
  21. Agent selon l'une des revendications 1 à 20, caractérisé en ce qu'il présente comme additifs ceux choisis parmi des vitamines, des électrolytes, l'allantoïne, le D-panthénol, l'acide hyaluronique, des mucopolysaccharides, des colorants, des substances parfumées, des conservateurs, des agents humectants.
  22. Agent selon l'une des revendications 1 à 21, caractérisé en ce qu'il présente en plus des produits à base de cires.
  23. Agent selon l'une des revendications 1 à 22, caractérisé en ce qu'il contient en plus comme additifs des lécithines.
  24. Agent selon l'une des revendications 1 à 23, destiné à soigner les lésions du tissu cutané.
  25. Procédé de préparation d'agents selon l'une des revendications 1 à 23, caractérisé en ce que l'on prépare l'extrait d'oignon, dans lequel des additifs solubles peuvent être inclus, et la phase grasse, dans laquelle des additifs solubles peuvent être incorporés, et ensuite on prépare la phase aqueuse, qui peut présenter des additifs solubles et notamment des alcools, puis on émulsionne la phase aqueuse et la phase huileuse à des températures dans la plage de 60 à 90°C ensemble avec un ou plusieurs émulsifiants ou mélanges de ceux-ci entre eux ou avec des co-émulsifiants et, après refroidissement, on ajoute les additifs éventuellement présents et on effectue un traitement approprié, ou bien on incorpore l'extrait d'oignon ensemble avec les additifs dans la phase grasse (huileuse), des alcools pouvant également être ajoutés en tant que solvants.
  26. Utilisation d'un agent selon l'une des revendications 1 à 23 pour préparer des compositions destinées au traitement, au soin ou à la prévention des lésions du tissu cutané.
  27. Utilisation selon la revendication 26, caractérisée en ce que la lésion du tissu cutané est un tissu cicatriciel.
  28. Utilisation selon la revendication 27, caractérisé en ce que le tissu cicatriciel est un tissu résultant de l'acné ou d'interventions de chirurgie esthétique.
  29. Utilisation selon la revendication 26, caractérisé en ce que les lésions du tissu cutané sont des vergetures de grossesse.
  30. Utilisation selon la revendication 26, caractérisé en ce que les lésions du tissu cutané sont des lésions du tissu cutané résultant de plaies de coupure, de plaies d'opérations, de brûlures ou d'une dégénérescence liée à l'âge.
EP02760209A 2001-07-03 2002-07-01 Agent contenant de la graisse(de l'huile) et un extrait d'oignon, sa production et son utilisation pour soigner, prevenir ou traiter des tissus cutanes endommages, notamment des cicatrices Expired - Lifetime EP1401466B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05009586A EP1566179B1 (fr) 2001-07-03 2002-07-01 Agent contenant de la graisse (de l'huile) et de l'extrait d'oignon, sa production et son utilisation
DK02760209T DK1401466T3 (da) 2001-07-03 2002-07-01 Fedtstofholdigt (olieholdigt) middel, indeholdende lögekstrakt, dets fremstillling og dets anvendelse til pleje, forebyggelse eller behandling af beskadiget hudvæv, især ar

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10132003A DE10132003A1 (de) 2001-07-03 2001-07-03 Fett(öl)haltiges Mittel, enthaltend Zwiebelextrakt, seine Herstellung und seine Verwendung zur Pflege, Vorbeugung oder Behandlung von geschädigtem Hautgewebe, insbesondere von Narben
DE10132003 2001-07-03
PCT/EP2002/007216 WO2003004043A1 (fr) 2001-07-03 2002-07-01 Agent contenant de la graisse(de l'huile) et un extrait d'oignon, sa production et son utilisation pour soigner, prevenir ou traiter des tissus cutanes endommages, notamment des cicatrices

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP05009586A Division EP1566179B1 (fr) 2001-07-03 2002-07-01 Agent contenant de la graisse (de l'huile) et de l'extrait d'oignon, sa production et son utilisation

Publications (2)

Publication Number Publication Date
EP1401466A1 EP1401466A1 (fr) 2004-03-31
EP1401466B1 true EP1401466B1 (fr) 2005-05-04

Family

ID=7690321

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05009586A Expired - Lifetime EP1566179B1 (fr) 2001-07-03 2002-07-01 Agent contenant de la graisse (de l'huile) et de l'extrait d'oignon, sa production et son utilisation
EP02760209A Expired - Lifetime EP1401466B1 (fr) 2001-07-03 2002-07-01 Agent contenant de la graisse(de l'huile) et un extrait d'oignon, sa production et son utilisation pour soigner, prevenir ou traiter des tissus cutanes endommages, notamment des cicatrices

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05009586A Expired - Lifetime EP1566179B1 (fr) 2001-07-03 2002-07-01 Agent contenant de la graisse (de l'huile) et de l'extrait d'oignon, sa production et son utilisation

Country Status (19)

Country Link
US (3) US20040151793A1 (fr)
EP (2) EP1566179B1 (fr)
KR (1) KR20040012913A (fr)
CN (1) CN1522150A (fr)
AT (3) AT503467B1 (fr)
AU (1) AU2002325856B2 (fr)
BG (1) BG108461A (fr)
BR (1) BR0210479A (fr)
DE (3) DE10132003A1 (fr)
DK (1) DK1401466T3 (fr)
EA (1) EA006440B1 (fr)
ES (3) ES2242055T3 (fr)
HU (1) HU230156B1 (fr)
IL (2) IL159193A0 (fr)
MX (1) MXPA04000002A (fr)
PL (1) PL205598B1 (fr)
PT (1) PT1401466E (fr)
UA (1) UA74891C2 (fr)
WO (1) WO2003004043A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10206257C1 (de) * 2002-02-15 2003-06-26 Beiersdorf Ag Massagegerät und dessen Verwendung
FR2845287B1 (fr) * 2002-10-02 2007-08-17 Lucas Meyer Cosmetics Nouvelles formulations cosmetiques a base d'un agent epaississant et leurs applications
DE10347487A1 (de) * 2003-09-30 2005-04-21 Kneipp Werke Kneipp Mittel Zen Kosmetische oder dermatologische Zusammensetzung zur topischen Verwendung
DE102004008440A1 (de) * 2004-02-19 2005-09-22 Stockhausen Gmbh Kosmetisches und/oder dermatologisches Mittel zur Steigerung des endogenen Lipidgehaltes der Haut
ITRM20040177A1 (it) * 2004-04-07 2004-07-07 Atika Soulimani Miscela cosmetica per capelli.
FR2876031A1 (fr) * 2004-10-01 2006-04-07 Ammar Taleb Composition phytotherapique pour le traitement des brulures
FR2877219B1 (fr) * 2004-10-28 2007-03-09 Fatima Basri Composition utilisee en cosmetique ou en pharmacologie pour stimuler la synthese du collagene
US7399783B2 (en) * 2005-06-22 2008-07-15 The Quigley Corporation Methods for the treatment of scar tissue
US20090022826A1 (en) * 2007-07-20 2009-01-22 Shrier David L Multi-step method of pain and/or inflammation treatment
KR101380241B1 (ko) 2007-07-27 2014-04-01 가부시키가이샤 시세이도 수중유형 유화 자외선 차단 화장료
FR2921263B1 (fr) * 2007-09-20 2014-05-16 Oreal Composition cosmetique de maquillage et/ou de soin comprenant au moins une cire ester particuliere et exemple de cire de polyethylene
FR2921266B1 (fr) * 2007-09-20 2012-06-01 Oreal Composition cosmetique de maquillage et/ou de soin comprenant au moins une cire ester et exempte d'huile apolaire
ES2525526T3 (es) * 2008-10-31 2014-12-26 Shiseido Company, Ltd. Composición de emulsión aceite/agua
CN101411499B (zh) * 2008-11-20 2012-05-23 南京农业大学 大蒜、洋葱复合精油与抗氧化剂维生素类复配软胶囊
PT2400951T (pt) * 2009-02-25 2018-11-26 Mayne Pharma Llc Composições de espuma tópica
KR20110023367A (ko) * 2009-08-31 2011-03-08 (주)아모레퍼시픽 넥 케어방법 및 상기 방법을 포함하는 넥 케어키트
JP5227991B2 (ja) * 2010-03-30 2013-07-03 株式会社 資生堂 Ｏ／ｗ乳化組成物
US20110243874A1 (en) 2010-04-01 2011-10-06 Rajan Keshav Panandiker Care polymers
DE102011006982A1 (de) * 2011-04-07 2012-10-11 Beiersdorf Ag Zubereitungen mit einem langanhaltenden floralen Duft ohne 4-(4-Hydroxy-4-methylpentyl)-3-cyclohexencarboxaldehyd
CA2837526C (fr) 2011-06-24 2019-07-09 Merz Pharma Gmbh & Co. Kgaa Composition comprenant un extrait d'oignon et des liposomes
JP5891651B2 (ja) * 2011-08-19 2016-03-23 株式会社池田模範堂 角層細胞分化正常化用皮膚外用剤
DE102012000430B4 (de) 2011-11-24 2021-11-04 Farco-Pharma Gmbh Zusammensetzung für die topische Anwendung I
WO2013126697A1 (fr) * 2012-02-23 2013-08-29 Toth Rita Compositions transdermiques et procédés de traitement des vergetures
KR101397114B1 (ko) * 2012-06-21 2014-05-19 동성제약주식회사 흉터 치료용 피부외용제 조성물
RU2686307C2 (ru) * 2012-12-14 2019-04-25 Мерц Фарма Гмбх Энд Ко. Кгаа Пластырь, содержащий экстракт лука
JP2014118399A (ja) * 2012-12-19 2014-06-30 L'oreal Sa 無水化粧料組成物
JP2014162756A (ja) * 2013-02-26 2014-09-08 Kowa Company Ltd パンテノール類を含有する含水組成物
TWI610687B (zh) * 2013-11-13 2018-01-11 愛茉莉太平洋股份有限公司 使用天然乳化劑的低黏度化妝品組成物
US9226890B1 (en) 2013-12-10 2016-01-05 Englewood Lab, Llc Polysilicone base for scar treatment
US20150238403A1 (en) * 2014-02-21 2015-08-27 Amorepacific Corporation Low viscous cosmetic composition using a natural emulsifying agent
WO2016049404A1 (fr) 2014-09-26 2016-03-31 The Procter & Gamble Company Substrats contenant des compositions réduisant les mauvaises odeurs
DE202014105057U1 (de) * 2014-10-22 2014-11-12 Tissma UG (haftungsbeschränkt) Handhygiene-Kosmetikum
CN105012228B (zh) * 2015-08-17 2018-04-20 郑州和济生物科技股份有限公司 防止疤痕形成及早期修复的玻尿酸硅凝胶组合物及制备方法
CN105381007B (zh) * 2015-11-16 2019-10-25 北京工商大学 具有美白功效的外用中药组合物、制剂及其制备方法和用途
WO2017165615A1 (fr) 2016-03-24 2017-09-28 The Procter & Gamble Company Compositions de soins capillaires comprenant des compositions capables de réduire les mauvaises odeurs
CN106138521A (zh) * 2016-06-28 2016-11-23 郑州雷曼药业有限公司 一种疤痕修复凝胶及其制备方法
CN105998573A (zh) * 2016-07-07 2016-10-12 无比滴（广东）药业有限公司 一种修复疤痕的外用剂及其制备方法
US20180305638A1 (en) * 2016-09-30 2018-10-25 Reimar C Bruening Non-alcoholic fragrances, composition and manufacture
DE102017105010A1 (de) 2017-02-24 2018-08-30 Farco-Pharma Gmbh Zusammensetzung, insbesondere Gel, zur Anwendung im Urogenitaltrakt
FR3065373B1 (fr) * 2017-04-21 2020-02-07 Jean-Noel Thorel Composition comprenant un extrait de cognassier pour le traitement du prurit et de la dermatite atopique
KR102106813B1 (ko) 2017-06-09 2020-05-06 주식회사 코스메카코리아 양파 추출물을 포함하는 피부 손상 예방 및 피부 재생 촉진용 조성물 및 그 제조방법
EP4108228A1 (fr) 2017-10-10 2022-12-28 The Procter & Gamble Company Composition d'hygiène personnelle transparente sans sulfate comprenant un sel inorganique faible
US10792384B2 (en) 2017-12-15 2020-10-06 The Procter & Gamble Company Rolled fibrous structures comprising encapsulated malodor reduction compositions
CN110151624A (zh) * 2019-06-13 2019-08-23 广州方媚化妆品有限公司 妊娠纹涂抹修复精华乳
US11980679B2 (en) 2019-12-06 2024-05-14 The Procter & Gamble Company Sulfate free composition with enhanced deposition of scalp active
RU2731527C1 (ru) * 2020-01-28 2020-09-03 Кирилл Александрович Новиков Способ устранения рубцовых изменений кожи
WO2021173203A1 (fr) 2020-02-27 2021-09-02 The Procter & Gamble Company Compositions antipelliculaires contenant du soufre ayant une efficacité et une esthétique améliorées
WO2021257018A1 (fr) * 2020-06-15 2021-12-23 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Compositions topiques anti-cicatrice et anti-âge
US11819474B2 (en) 2020-12-04 2023-11-21 The Procter & Gamble Company Hair care compositions comprising malodor reduction materials
KR102502443B1 (ko) * 2021-02-08 2023-02-23 바이오스펙트럼 주식회사 달맞이꽃의 열수 추출물을 유효성분으로 포함하는 튼살 예방, 개선, 또는 치료를 위한 조성물
US11771635B2 (en) 2021-05-14 2023-10-03 The Procter & Gamble Company Shampoo composition
US11986543B2 (en) 2021-06-01 2024-05-21 The Procter & Gamble Company Rinse-off compositions with a surfactant system that is substantially free of sulfate-based surfactants
DE102021122238A1 (de) 2021-08-27 2023-03-02 Nilgün Akgül Verfahren zur Herstellung eines Präparats, Präparat und Verwendung desselben

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1492823A (en) * 1921-09-09 1924-05-06 Woll Anna Ointment
GB493378A (en) * 1937-04-07 1938-10-07 George Megyesy Improvements in preparations for treating the hair
US3582361A (en) * 1963-10-12 1971-06-01 Dragoco Gerberding Co Gmbh Food flavoring compositions and process of making and using same
GB1130631A (en) * 1965-03-10 1968-10-16 Unilever Ltd Edible products
US3770463A (en) * 1971-09-20 1973-11-06 Gen Foods Corp Flavor enhancing composition for foodstuffs
US4049831A (en) * 1973-10-31 1977-09-20 Kikkoman Shoyu Co., Ltd. Novel composition containing fats or oils and method for manufacturing same
CH641646A5 (fr) * 1979-12-07 1984-03-15 Maggi Ag Procede de fabrication d'un agent aromatisant.
EP0153881A2 (fr) * 1984-03-02 1985-09-04 The Johns Hopkins University Traitement d'allergies et d'états inflammatoires
ATE129129T1 (de) * 1985-04-24 1995-11-15 Univ Bar Ilan Oxidationswiderstandsfähige, essbare fettzusammensetzungen, die ein aus pflanzlichem gewebe extrahiertes, aktives oxidation verhinderndes mittel enthalten.
DE3644677A1 (de) * 1986-12-30 1988-07-14 Mohamed Roshdy Dr Ismail Mittel zur verbesserung der bluteigenschaft
DE3723248A1 (de) * 1987-07-14 1989-01-26 Walter Dorsch Verwendung von thiosulfinsaeurederivaten zur behandlung von entzuendungserkrankungen
AU610551B2 (en) * 1987-12-23 1991-05-23 Psoricur Ltd. Therapeutical compositions against psoriasis
US4956429A (en) * 1989-03-01 1990-09-11 Penick Corporation Method of making a coca leaf flavor extract
JP2875308B2 (ja) * 1989-11-22 1999-03-31 湧永製薬株式会社 Ｓ−アリルシステイン高濃度含有組成物の製造方法
FR2681531B1 (fr) * 1991-09-20 1993-12-24 Abdallah Gharib Un nouveau procede de preparation de l'extrait de loignon pharmacologiquement actif.
US5624906A (en) * 1994-12-08 1997-04-29 Lever Brothers Company, Division Of Conopco, Inc. Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds
US5607715A (en) * 1995-03-20 1997-03-04 The Procter & Gamble Company Flavored cooking oil having reduced room aroma
US5859270A (en) * 1996-03-13 1999-01-12 Cargill, Incorporated Method for preparation of purified monoglycerides; and, products
DE19628284C1 (de) * 1996-07-12 1997-12-18 Georgios Dr Pandalis Verwendung von Bärlauch zur Behandlung oder Prophylaxe von Hyperkeratosen
AU3692097A (en) * 1996-08-02 1998-02-25 Plum Kemi Produktion A/S An oil-in-water emulsion for use on human skin for cleansing, preserving or improving the condition of the skin
IL121320A (en) * 1997-02-23 2000-12-06 Ibr Ltd Extracts from cells or tissue of organisms which are capable of entering dormancy for inhibition of proliferation of target cells or tissue
GB9709082D0 (en) * 1997-05-06 1997-06-25 Ciba Geigy Ag Organic compositions
US5885581A (en) * 1997-09-11 1999-03-23 Merz, Incorporated Composition and method for improvement of the appearance of scars
US6200570B1 (en) * 1997-12-08 2001-03-13 Counsel Of Scientific And Industrial Research Herbal formulation useful as a therapeutic and cosmetic applications for the treatment of general skin disorders
DE19934943B4 (de) * 1999-07-26 2007-08-02 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
FR2819414A1 (fr) * 2001-01-15 2002-07-19 Cognis France Sa Preparations cosmetiques et/ou pharmaceutiques comprenant des extraits de plantes dites a resurrection

Also Published As

Publication number Publication date
PL205598B1 (pl) 2010-05-31
KR20040012913A (ko) 2004-02-11
DE50203013D1 (de) 2005-06-09
EP1401466A1 (fr) 2004-03-31
ES2217983A1 (es) 2004-11-01
ES2217983B1 (es) 2005-11-16
AT503467B1 (de) 2010-04-15
US20040151793A1 (en) 2004-08-05
MXPA04000002A (es) 2005-06-06
IL159193A0 (en) 2004-06-01
US20100247689A1 (en) 2010-09-30
EA006440B1 (ru) 2005-12-29
PT1401466E (pt) 2005-06-30
HUP0400375A3 (en) 2012-09-28
EP1566179A2 (fr) 2005-08-24
AT503467A5 (de) 2007-10-15
DE10132003A1 (de) 2003-01-30
HU230156B1 (hu) 2015-09-28
ATE411034T1 (de) 2008-10-15
US20190083559A1 (en) 2019-03-21
UA74891C2 (en) 2006-02-15
WO2003004043A1 (fr) 2003-01-16
AU2002325856B2 (en) 2005-01-06
CN1522150A (zh) 2004-08-18
DK1401466T3 (da) 2005-07-25
HUP0400375A2 (hu) 2004-09-28
BR0210479A (pt) 2004-08-10
EP1566179B1 (fr) 2008-10-15
EA200400137A1 (ru) 2004-06-24
EP1566179A3 (fr) 2005-11-09
ES2315756T3 (es) 2009-04-01
IL159193A (en) 2010-11-30
PL364491A1 (en) 2004-12-13
ATE294589T1 (de) 2005-05-15
DE50212921D1 (de) 2008-11-27
BG108461A (en) 2005-01-31
ES2242055T3 (es) 2005-11-01

Similar Documents

Publication Publication Date Title
EP1401466B1 (fr) Agent contenant de la graisse(de l'huile) et un extrait d'oignon, sa production et son utilisation pour soigner, prevenir ou traiter des tissus cutanes endommages, notamment des cicatrices
TW592714B (en) Composition to enhance permeation of topical skin agents
EP0801946A2 (fr) Utilisation de salicine comme actif contre l'irritation dans des compositions cosmétiques ou topiques dermatologiques
EP2395966B1 (fr) Préparation cosmétique pour le soin de la peau
EP2029089B1 (fr) Émulsion h/e pour le soin de la main
DE202012013021U1 (de) Hautpflegeformulierung
CN111801108A (zh) 局部皮肤护理组合物
DE10250755B4 (de) Verschäumbare Zusammensetzung auf Basis einer O/W-Emulsion mit einer Kombination aus einem Emulgator auf Silikonbasis und einem anionischen Tensid mit verbesserter Hautwirkung, deren Herstellung und deren Verwendung
DE10324256B4 (de) Lipid-Tranferprotein-Systeme und deren kosmetische/dermatologische Anwendung
EP1541126A1 (fr) Composition cosmétique ou dermatologique comprenant la combinaison d'un agent colorant vert et d'un agent anti-inflammatoire
DE10136077A1 (de) Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin und/oder Kreatininderivaten mit Kreatin und/oder seinen Derivaten
EP1721601A1 (fr) Utilisation de taurine pour augmenter la synthèse des lipides cutanés
DE10128910A1 (de) Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
EP0801945A2 (fr) Utilisation de glucosides de l'acide férilique comme actifs contre l'irritation dans des compositions cosmétiques ou topiques dermatologiques
DE10352367A1 (de) Verwendung von Licochalkon A gegen Rosacea
EP1529520A1 (fr) Utilisation de licochalcone A ou d'un extrait de Radix Glycyrrhizae inflatae contenant du licochalcone A contre la hyperpigmentation postinflammatoire
WO2009115216A1 (fr) Utilisation d'un constituant ou d'un extrait de baobab en cas de maladies de peau
EP1676561A2 (fr) Compositions contenant un système polyphasé biocatalytique et son utilisation
WO1997039732A1 (fr) Utilisation d'extrait de salix nigra comme principe actif anti-irritation dans des preparations dermatologiques cosmetiques et dermatologiquestopiques
AT501699B1 (de) Verschäumbare zusammensetzung auf basis einer o/w- emulsion, deren herstellung und deren verwendung
DE19615576A1 (de) Verfahren zur Herstellung von Mono- und/oder Diglucosiden des Glabridins und deren Verwendung als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
DE10352368A1 (de) Verwendung von Licochalkon A zur Behandlung von Insektenstichen
DE202006018519U1 (de) Feuchtigkeitsspendende wasserhaltige Sanddorn-Hautpflegepräparate (Emulsionen)
DE10204526A1 (de) Kosmetische und dermatologische Zubereitungen mit Eucalyptusöl in Kombination mit weiteren Wirk- und Inhaltsstoffen
DE19615574A1 (de) Verwendung von Mono- und/oder Diglucosiden von Gentisin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 35/78 A

Ipc: 7A 61P 17/02 B

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REF Corresponds to:

Ref document number: 50203013

Country of ref document: DE

Date of ref document: 20050609

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20050506

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20050402406

Country of ref document: GR

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20050908

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E000112

Country of ref document: EE

Effective date: 20050722

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2242055

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

ET Fr: translation filed
26N No opposition filed

Effective date: 20060207

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: MERZ PHARMA GMBH & CO. KGAA

Free format text: MERZ PHARMA GMBH & CO. KGAA#ECKENHEIMER LANDSTRASSE 100#60318 FRANKFURT (DE) -TRANSFER TO- MERZ PHARMA GMBH & CO. KGAA#ECKENHEIMER LANDSTRASSE 100#60318 FRANKFURT (DE)

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 50203013

Country of ref document: DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20210611

Year of fee payment: 20

Ref country code: SK

Payment date: 20210615

Year of fee payment: 20

Ref country code: FR

Payment date: 20210611

Year of fee payment: 20

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20210729 AND 20210804

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20210730

Year of fee payment: 20

Ref country code: TR

Payment date: 20210611

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20210701

Year of fee payment: 20

Ref country code: AT

Payment date: 20210721

Year of fee payment: 20

Ref country code: EE

Payment date: 20210722

Year of fee payment: 20

Ref country code: BG

Payment date: 20210720

Year of fee payment: 20

Ref country code: FI

Payment date: 20210721

Year of fee payment: 20

Ref country code: CY

Payment date: 20210601

Year of fee payment: 20

Ref country code: MC

Payment date: 20210722

Year of fee payment: 20

Ref country code: LU

Payment date: 20210726

Year of fee payment: 20

Ref country code: IE

Payment date: 20210721

Year of fee payment: 20

Ref country code: IT

Payment date: 20210722

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20210726

Year of fee payment: 20

Ref country code: DE

Payment date: 20210729

Year of fee payment: 20

Ref country code: CH

Payment date: 20210722

Year of fee payment: 20

Ref country code: BE

Payment date: 20210726

Year of fee payment: 20

Ref country code: SE

Payment date: 20210722

Year of fee payment: 20

Ref country code: GB

Payment date: 20210726

Year of fee payment: 20

Ref country code: DK

Payment date: 20210722

Year of fee payment: 20

Ref country code: ES

Payment date: 20210810

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 50203013

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20220701

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20220630

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20220630

REG Reference to a national code

Ref country code: SK

Ref legal event code: MK4A

Ref document number: E 179

Country of ref document: SK

Expiry date: 20220701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220630

Ref country code: CZ

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220701

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20220701

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220803

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 294589

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220701

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220701

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220711

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220701

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220702